The Field-in-field technique in esophageal cancer radiotherapy
Keywords:
Esophageal cancer, Field-in-field technique, RadiotherapyAbstract
Background and aim of the work: Radiotherapy plays an important role in the treatment of esophageal cancer at most stages. Some patients undergo T-shaped irradiation that includes the subclavicular region. In this procedure, the cervical region receives a higher dose of radiation than the lower thoracic region because of differences in thickness. We asked whether the field-in-field (FIF) technique would reduce the size of the hot region in T-shaped irradiation. Methods: Our study consisted of 16 patients with esophageal cancer; the prescribed dose was 40 Gy in 20 fractions. The conventional radiotherapy plan included 4 fields: anterior-posterior/posterior-anterior (AP/PA) parallel-opposed fields and right-anterior oblique and left-posterior oblique fields. The FIF plan included an additional subfield, which was generated by copying the PA field. The multileaf collimators of the subfield were manipulated to shield the areas of the planning target volume (PTV) receiving doses ≥107% of the prescribed dose on the beam’s eye view. After dose calculation, weight was shifted from the original PA field to the subfield until the hot spot disappeared. Results: The volumes of the PTV receiving 107% of the prescribed dose, the maximum doses (Dmax) to the PTV and spinal cord, and the homogeneity index of the PTV were significantly smaller in the FIF plan than in the conventional plan. Conclusions: These findings show that the FIF technique improves the dose homogeneity of the PTV and reduces the maximum dose to the spinal cord in thoracic esophageal cancer.Downloads
Published
Issue
Section
License
OPEN ACCESS
All the articles of the European Journal of Oncology and Environmental Health are published with open access under the CC-BY Creative Commons attribution license (the current version is CC-BY, version 4.0 http://creativecommons.org/licenses/by/4.0/). This means that the author(s) retain copyright, but the content is free to download, distribute and adapt for commercial or non-commercial purposes, given appropriate attribution to the original article.
The articles in the previous edition of the Journal (European Journal of Oncology) are made available online with open access under the CC-BY Creative Commons attribution license (the current version is CC-BY, version 4.0 http://creativecommons.org/licenses/by/4.0/).
Upon submission, author(s) grant the Journal the license to publish their original unpublished work within one year, and the non exclusive right to display, store, copy and reuse the content. The CC-BY Creative Commons attribution license enables anyone to use the publication freely, given appropriate attribution to the author(s) and citing the Journal as the original publisher. The CC-BY Creative Commons attribution license does not apply to third-party materials that display a copyright notice to prohibit copying. Unless the third-party content is also subject to a CC-BY Creative Commons attribution license, or an equally permissive license, the author(s) must comply with any third-party copyright notices.